These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1828768)

  • 1. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
    Kato K; Nakayama K; Ohta M; Murakami N; Murakami K; Mizota M; Miwa I; Okuda J
    Eur J Pharmacol; 1991 Feb; 193(2):185-91. PubMed ID: 1828768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
    Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.
    Kato K; Nakayama K; Ohta M; Murakami N; Murakami K; Mizota M; Miwa I; Okuda J
    Jpn J Pharmacol; 1990 Dec; 54(4):355-64. PubMed ID: 2128352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
    Nakayama K; Murakami N; Ohta M; Kato K; Ida K; Mizota M; Miwa I; Okuda J
    Eur J Pharmacol; 1995 Mar; 276(1-2):77-83. PubMed ID: 7781698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
    Cameron NE; Cotter MA; Dines KC; Maxfield EK; Carey F; Mirrlees DJ
    Diabetologia; 1994 Jul; 37(7):651-63. PubMed ID: 7958535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
    Yasuda H; Sonobe M; Hisanaga T; Kawabata T; Maeda K; Kikkawa R; Shigeta Y
    Metabolism; 1992 Jul; 41(7):778-82. PubMed ID: 1320179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent aldose reductase inhibitors having a hydantoin structure.
    Miwa I; Hirano M; Inagaki K; Belbeoc'h C; Okuda J
    Biochem Pharmacol; 1987 Sep; 36(17):2789-94. PubMed ID: 3115267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats.
    Nakayama K; Murakami N; Ohta M; Kato K; Notsu T; Mizota M; Miwa I; Okuda J
    Eur J Pharmacol; 1995 Mar; 276(1-2):85-91. PubMed ID: 7781699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
    Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V
    J Pharmacol Sci; 2008 Jul; 107(3):231-7. PubMed ID: 18635918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
    Yasuda H; Sonobe M; Yamashita M; Terada M; Hatanaka I; Huitian Z; Shigeta Y
    Diabetes; 1989 Jul; 38(7):832-8. PubMed ID: 2525492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
    Cameron NE; Cotter MA; Robertson S
    Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.